COVID-19 Science & Society

How will the world look like in 2022? Is SARS-CoV-2 here to stay with us? While some countries are opening towards normal life, albeit with cautious optimism, others are experiencing the hardest disease burden and public health crisis so far. Will vaccines be effective against new variants and how long the protection will last? What do we know so far about long COVID? Which patient populations could benefit most from emerging therapeutic options? Would there be resistance to new therapies? Subscribe to the COVID-19 Science & Society podcast to find out more on the most relevant and timely topics concerning the COVID pandemic.

#10 Ravi Gupta - The Omicron Variant

Ravindra Gupta, MA, MPH, BMBCh, PhD, FRCP, FRCPath, FMedSciUniversity of Cambridge, United Kingdom

12-08
21:04

#9 Laura Waters - Vaccines and the Immunosuppressed

Laura Waters, MD, FRCPCentral & North West London NHS Foundation Trust, United Kingdom

11-25
24:47

#8 Monica Gandhi - Vaccine Schedules

Monica Gandhi, MD, MPHUniversity of California San Francisco, United States

10-14
23:43

#7 Jean Nachega - Scaling up Vaccine Access

Jean Nachega MD, PhD, MPH, FRCP, FAASUniversity of Pittsburgh / Johns Hopkins University, United States Stellenbosch University, South Africa

09-30
24:22

#6 Karine Lacombe - Vaccine Safety

Karine Lacombe, MD, PhDHĂ´pital Saint Antoine Paris, France

09-16
23:33

#5 Michel Kazatchkine - Preparedness

Michel Kazatchkine, MDThe Global Health Center, Graduate Institute for International Affairs and DevelopmentReferences:The Independent Panel for Pandemic Preparedness & Response

07-15
23:28

#4 Kathryn Stephenson - Variants & Vaccines

Kathryn Stephenson, MD, MPHBeth Israel Deaconess Medical Center

07-07
24:32

#3 Sanjay Bhagani - The Delta Variant

Sanjay Bhagani, BSc, FRCPConsultant Physician in Infectious Diseases/HIV Medicine and General (internal) Medicine, Royal Free Hospital

06-30
22:56

#2 Daniel Kuritzkes - Monoclonal Antibodies

Daniel Kuritzkes, MDBrigham and Women's Hospital; Harvard Medical School, United StatesConflict of Interest DisclosureReceipt of grants/research support from Atea, Gilead, Merck, and ViiVReceipt of honoraria or consultation fees from Abpro, Atea, Decoy, Gilead, GlaxoSmithKline, Merck, Novartis, Rigel, ViiV

06-23
20:54

#1 Carlos del Rio - Long-term complications of COVID-19

Long-term complications of COVID-19 Carlos del Rio, MD Emory School of Medicine & Grady Health System, United States Conflict of interest disclosure Carlos del Rio has received honoraria / consultation fees from Sanofi-Pasteur References US CDC - Post-COVID Conditions https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html#:~:text=Post%2DCOVID%20conditions%20are%20a,can%20have%20post%2DCOVID%20conditions. UK Office for National Statistics - Prevalence of Ongoing Symptoms Fol...

06-11
21:50

Recommend Channels